Company Analysis
Sign in

Kymera Therapeutics, Inc. (KYMR)

Nasdaq: KYMR · Biological Products, (No Diagnostic Substances) · Watertown, MA · filing with the SEC since 2020
Full chart Alerts Compare
Grade5.1
◀ Past 6.2● Present 5.3▶ Future 3.6
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

34 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Kymera Therapeutics, Inc.’s names, not what it holds today.

Patents granted
34
34 utility, 1976 to Dec 31, 2025
Granted in 2025
4
Against 11 in 2024 and 10 in 2023
Applications published
101
30 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Organic fine chemistry23
Pharmaceuticals10
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Kymera Therapeutics, Inc. its own name
named as the applicant on its applications, in US
0 granted
101 published
Kymera Therapeutics, Inc. its own name
US, as the owner printed on each patent
34 granted
0 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 16, 202512,497,402IRAK4 degraders and uses thereofPharmaceuticalsKymera Therapeutics, Inc.
Oct 28, 202512,454,520Protein degraders and uses thereofOrganic fine chemistryKymera Therapeutics, Inc.
Mar 25, 202512,258,341IRAK degraders and uses thereofOrganic fine chemistryKymera Therapeutics, Inc.
Jan 7, 202512,187,744IRAK4 degraders and synthesis thereofOrganic fine chemistryKymera Therapeutics, Inc.
Dec 24, 202412,171,768IRAK4 degraders and uses thereofPharmaceuticalsKymera Therapeutics, Inc.
Dec 17, 202412,168,057IRAK degraders and uses thereofPharmaceuticalsKymera Therapeutics, Inc.
Nov 26, 202412,150,995IRAK degraders and uses thereofOrganic fine chemistryKymera Therapeutics, Inc.
Sep 24, 202412,097,261CDK2 degraders and uses thereofOrganic fine chemistryKymera Therapeutics, Inc.
Sep 17, 202412,091,411IRAK degraders and uses thereofOrganic fine chemistryKymera Therapeutics, Inc.
Sep 3, 202412,077,555STAT degraders and uses thereofOrganic fine chemistryKymera Therapeutics, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 25, 20252025/0388566PROTEIN DEGRADERS AND USES THEREOFOrganic fine chemistryKymera Therapeutics, Inc.
Dec 11, 20252025/0375526IRAK DEGRADERS AND USES THEREOFOrganic fine chemistryKymera Therapeutics, Inc.
Dec 11, 20252025/0375460STAT DEGRADERS AND USES THEREOFPharmaceuticalsKymera Therapeutics, Inc.
Nov 20, 20252025/0352535MDM2 DEGRADERS AND USES THEREOFPharmaceuticalsKymera Therapeutics, Inc.
Oct 30, 20252025/0333417IRAK DEGRADERS AND USES THEREOFOrganic fine chemistryKymera Therapeutics, Inc.
Oct 23, 20252025/0325673IRAK DEGRADERS AND USES THEREOFPharmaceuticalsKymera Therapeutics, Inc.
Sep 4, 20252025/0275970SMARCA DEGRADERS AND USES THEREOFOrganic fine chemistryKymera Therapeutics, Inc.
Jul 3, 20252025/0214977STAT6 INHIBITORS AND USES THEREOFPharmaceuticalsKymera Therapeutics, Inc.
Jul 3, 20252025/0214969PROTEIN DEGRADERS AND USES THEREOFOrganic fine chemistryKymera Therapeutics, Inc.
Jul 3, 20252025/0213586STAT6 INHIBITORS AND USES THEREOFPharmaceuticalsKymera Therapeutics, Inc.
What it applied for, 2024 to 2025: Organic fine chemistry 30 · Pharmaceuticals 15.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton KYMR · research, not advice